Literature DB >> 30086083

Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma.

Yukari Miyadera1, Takafumi Naito, Takahiro Yamada, Junichi Kawakami.   

Abstract

BACKGROUND: Daptomycin, a cyclic lipopeptide antibiotic, displays high plasma protein binding. This study developed the simple method of liquid chromatographic separation using a core-shell octadecylsilyl microparticulate coupled to tandem mass spectrometry for the quantitation of total and free daptomycin in human plasma.
METHODS: Free daptomycin in plasma was obtained by centrifugal ultrafiltration. Deproteinized plasma specimens were directly separated using a core-shell octadecylsilyl microparticulate with isocratic elution. The mass spectrometer was run in positive-ion electrospray ionization mode. This method was applied to the quantitation of plasma samples in patients treated with intravenous daptomycin.
RESULTS: Daptomycin and diazepam as an internal standard were eluted with a total run time of 10 minutes. The calibration curves of total and free daptomycin in human plasma were linear over the concentration ranges of 1-100 and 0.1-10 mcg/mL, respectively. The lower limits of quantitation of the total and free daptomycin in human plasma were 1.0 and 0.1 mcg/mL, respectively. Their extraction recovery rates in nonfiltrated and ultrafiltrated plasma samples were 106.1% and 98.2%, respectively. Total and free daptomycin did not exhibit any matrix effects in human plasma. The intraday and interday accuracies and imprecisions of total daptomycin were 88.7%-106.0% and 98.7%-105.9%, and within 4.1% and 10.4%, whereas those of free daptomycin were 86.8%-101.6% and 103.0%-107.8%, and within 14.6% and 14.6%, respectively. The plasma concentration ranges of total and free daptomycin in 15 infected patients were 3.01-34.1 and 0.39-3.64 mcg/mL, respectively. The plasma protein binding rate of daptomycin ranged from 80.8% to 94.9%.
CONCLUSIONS: The present simple method with an acceptable analytical performance can be helpful for monitoring the pharmacokinetics of daptomycin in infected patients observed in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30086083     DOI: 10.1097/FTD.0000000000000535

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors.

Authors:  Yi Qian; Lu-Ning Sun; Yang-Jie Liu; Qiang Zhang; Jiang-Hao Xu; Zeng-Qing Ma; Xue-Hui Zhang; Hao Xu; Yong-Qing Wang
Journal:  Front Pharmacol       Date:  2019-07-30       Impact factor: 5.810

Review 2.  Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review.

Authors:  Carolina Osorio; Laura Garzón; Diego Jaimes; Edwin Silva; Rosa-Helena Bustos
Journal:  Antibiotics (Basel)       Date:  2021-03-05

Review 3.  Importance and Reality of TDM for Antibiotics Not Covered by Insurance in Japan.

Authors:  Fumiya Ebihara; Yukihiro Hamada; Hideo Kato; Takumi Maruyama; Toshimi Kimura
Journal:  Int J Environ Res Public Health       Date:  2022-02-22       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.